A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Dose-Response Relationships of Acid-Inhibitory Effect and Efficacy of TAK-438 (20 mg, 40 mg) in Patients with PPI-Resistant Erosive Esophagitis.

Trial Profile

A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Dose-Response Relationships of Acid-Inhibitory Effect and Efficacy of TAK-438 (20 mg, 40 mg) in Patients with PPI-Resistant Erosive Esophagitis.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2016

At a glance

  • Drugs Vonoprazan (Primary)
  • Indications Reflux oesophagitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 24 May 2016 Results presented at the Digestive Disease Week 2016
    • 07 Feb 2014 According to the ClinicalTrials.gov record, status changed to completed.
    • 03 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top